Abstract
Minocycline is a new member of the tetracycline family which has a broad antibacterial spectrum and is more potent than tetracycline. We have recently obtained the result described below through the clinical and experimental studies of minocycline.
1 The minimal inhibitory concentration of minocycline was measured by an agar plate dilution method. Minocycline inhibited the growth of 60 strains of coagulase-positive Staphylococcus aureus at (0.19-1.56mcg/ml93.3%) or(12.5-50mcg/ml6.3%)
2 The blood level of minocycline was determined in 3 adult cases. The maximal level reached 1.8mcg/ml on the average 2 hours after a single oral administration of 200 mg, and still 0.69 mcg/ml in 24 hours after the administration.
3 The urinary excretion of minocycline was studied in 3 adult cases. The urinary recovery was extremely low ranging in 5.3% in 12 hours by a single oral administration of 200mg.
4 In the clinical test of minocycline in otorhinolaryngological infection, it was found that the results were good in 26 cases of 34 (76%) by oral administration of 200 mg per day or by local aplication of 5 mg/ml solution.
5 Minocycline showed no side effect at all in oral and local medication.
